Related Experiment Video

Updated: May 27, 2026

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

Understanding the cardiovascular effects of incretin

Ji Sung Yoon1, Hyoung Woo Lee

  • 1Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.

Diabetes & Metabolism Journal
|November 24, 2011
PubMed

Insights

Novel diabetes drugs targeting the incretin pathway show promise for cardiovascular disease (CVD) by improving heart and blood vessel health beyond glucose control. Further trials are needed to confirm these benefits for patients with diabetes mellitus.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a major cause of mortality in diabetes mellitus patients.
  • Traditional glucose-lowering medications lack proven benefits for macrovascular complications.
  • The incretin pathway offers novel therapeutic targets for diabetes management.

Purpose of the Study:

  • To review the cardiovascular benefits of novel incretin-based therapies in diabetes.
  • To explore the mechanisms underlying the cardioprotective effects of GLP-1 receptor agonists.

Main Methods:

  • Review of existing literature on incretin pathway agents.
  • Analysis of studies investigating effects on myocardium, vascular endothelium, and atherogenesis.
  • Examination of impacts on weight, lipid profile, and blood pressure.

Main Results:

  • GLP-1 receptor agonists and DPP-4 inhibitors improve glycemic control via insulin and glucagon modulation.
  • These agents promote weight loss by affecting gastric emptying and appetite.
  • Evidence suggests beneficial effects on myocardium, vascular endothelium, inflammation, and atherosclerosis.
  • Positive impacts on lipid profiles and blood pressure are also observed.

Conclusions:

  • Incretin-based therapies demonstrate pleiotropic cardioprotective effects in diabetes, potentially independent of glucose lowering and weight loss.
  • Mechanisms involve both GLP-1R-dependent and -independent pathways.
  • Larger randomized controlled trials are essential to validate the clinical utility of these agents for CVD prevention in diabetic patients.
Keywords:
Cardiovascular diseasesDiabetes mellitusGlucagon-like peptide 1Incretins

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.